Cannabis Science (CBIS) Provides Guidance on the Company's New Year and Products, Developments and 'Initiatives in Action' for 2015
COLORADO SPRINGS, Colo., Feb. 2, 2015 /PRNewswire/ -- Cannabis Science, Inc. (OTCQB: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, today announced several updates and significant progress on product commercialization and key developments domestically and internationally from the Americas to Africa to Hong Kong, a key door to Asia.
Highlights
"Overall, the medical cannabis industry is booming and it doesn't show any signs of slowing down," said Raymond C. Dabney, the company's Director, President & CEO and Co-Founder. "In the next two years, a number of states are expected to consider the legalization of both recreational and medical cannabis. While recreational use is not a part of our business model, we do believe its public and legislative support is one of the key litmus tests for acceptance of medical cannabis." Please see sector growth charts from January 29, 2015 in the Huffington Post.
Dabney said Cannabis Science made great strides in 2014, establishing partnerships and joint ventures with partners around the world. He added that the company is ready to move to the next level in 2015 in terms of expansion of public awareness, commercialization of products, and expansion of capacity to address serious health issues in the U.S. and internationally. This includes the Company's African initiative. Also, not previously announced, Dabney and key team members recently returned from Hong Kong, where promising relationships were formed for the Company's many initiatives in Asia.
"One of the final steps in taking operations in 2015 to the next level is putting in place a strong media program," said Dabney. "We are proud to announce we have just retained top media experts to drive media interest in the Company and also in the Foundation." Forward looking media coverage will assist the Company's team in sharing and expanding on its core mission: to develop, produce, and commercialize truly novel therapeutic approaches for the treatment of critical ailments from cancer and infections to age-related illnesses and neurobehavioral disorders for patients in need. "And Cannabis Science's team is stronger that ever, enhanced by its collaboration with leading experts in drug development, medicinal characterization and clinical research," noted Dabney. Please see Cannabis Science's expanding Scientific Advisory Board.
New retail locations in two European countries as well as California
Cannabis Science is making final preparations to bring its products to market and has finalized preliminary retail locations in Spain and the Netherlands, and sites in California. With these successes, the Company expects an increase in demand in these jurisdictions, others that the Company has announced, and more being actively targeted.
These cannabis and cannabinoid-based products are currently ready for pre-clinical studies, self-medicating patient usage, and marketing release, sales and distribution. The Company is also developing processes to efficiently produce, distribute and market products along with the proper procurement of opt-in, informed consent data collection regarding patient outcomes. This will establish Cannabis Science with a vertically integrated product pipeline to accommodate varied established and emerging international markets.
The Cannabis Science product launch will begin in the Netherlands and Spain within the next week, and in California the following week.
A strong new partnership in Michigan
In the United States, Cannabis Science is leading the market in Michigan through its subsidiary, Michigan Green Technologies, LLC (MGT), which is recognized as the foremost resource for Michigan legislative initiatives and management consulting in respect of cannabinoid-based drug development, nutraceuticals, cosmeceuticals, and food supplements. Following a slight administrative delay, MGT is now poised to lead Michigan into a much larger and more successful version of the experience witnessed in Colorado.
Success in California
Cannabis Science also successfully renegotiated its agreement with Apothecary Genetics Investments LLC to purchase and license two northern California production farms with a combined total of 51 acres. The purchase includes all related equipment for cannabis cultivation and production for the state's substantial medical cannabis market. The Company is in the final stages of its preparations to launch new products throughout the California market, including extracts, oils, tinctures, tablets, and creams.
"The overall goal of Cannabis Science in the United States is to offer products as soon as it is legally possible in each state," said Dabney. "We know the medical need is there, and that means the market is poised and waiting for Cannabis Science in California and beyond."
Research around the world
In Spain and the Netherlands, Cannabis Science is working closely with the Mediwiet Foundation to conduct an observational study with patients who are self-treating with medicinal cannabis. Cannabis Science also began pre-clinical studies on its CBN patent in Italy and is collaborating with Unistraw in an exciting effort to produce proprietary formulations delivering a wide array of unique cannabis extracts and pure cannabinoid-based products.
The Company is also negotiating with groups in South American countries, such as Uruguay and Colombia, and is exploring similar opportunities in Mexico. All of these countries are part of the Company's fundamental plan to create a network for efficient licensing and distribution for medical cannabis formulations and products. The Company intends to add East Asia and Australasia to this network and will make further announcements as developments warrant.
Continued development of an African initiative
Through foundations like the Constituency for Africa, Cannabis Science is also developing political strategies for low-cost cannabis-based therapeutics to address the lack of access to pain medications and other needed treatments in Africa. This initiative has both philanthropic and commercial elements.
Cannabis Science had recently launched the Patient Access Centre and the Cannabis Science Research Foundation, among other things, to bring the public together to increase public awareness and generate humanitarian contributions to help patients in need.
Join the PAC (Patient Access Centre)
See the Cannabis Science Research Foundation Website
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.
Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.